Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results mdxhealth (NASDAQ: MDXH) reported fourth-quarter 2025 revenue of $29.5M (+19%) and full-year 2025 revenue of $107.9M (+20%). Gross profit rose to $69.6M for 2025 with gross margin at 64.5%. Adjusted EBITDA improved to ($1.1M) for 2025. Cash was $29.0M at year-end. The company reaffirmed 2026 revenue guidance of $137–140M and targets a 10% adjusted EBITDA margin exiting 2026.

#MDXH Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

www.stocktitan.net/news/MDXH/mdxhealth-anno...

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer mdxhealth (NASDAQ: MDXH) announced initiation of Genomic Prostate Score (GPS) testing in the UK ProtecT randomized trial to validate GPS in an Active Surveillance cohort.The ProtecT trial followed >1,500 men with localized prostate cancer for over two decades across Active Surveillance, Radical Prostatectomy, and Radiotherapy, providing long-term outcomes that the GPS-ProtecT study will leverage to test GPS's predictive power.This follows a prior ProMPT validation and aims to generate randomized clinical-trial evidence supporting GPS's clinical utility and potential influence on guidelines, payer coverage, and provider adoption.

#MDXH Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer

www.stocktitan.net/news/MDXH/mdxhealth-and-...

Most Searched, Tuesday December 30, 2025 – Crystal Equity Research

Most searched small-cap stocks, Tue Dec 30th - #RR #JBLU #RXRX #SLS #BITF #DNN #BTBT #SOPA #BBAI #SIDU #CETX #EKSO #TRON #TLRY #RDW #ONDS #MDXH #HYMC #CERS #BYND - More: crystalequityresearch.com/most-searche... - #smallcap

#MDXH Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025

www.stocktitan.net/news/MDXH/mdxhealth-repo...

Leading Indicators, Wednesday August 6, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Wed Aug 6th - #XTKG #TRUE #SEAT #RIGL #MDXH #LPSN #GO #FBRX #EHTH #DYN #CCLD #BTAI #AMWD #MBC #LANV #GB #CTEV #AGL - More: crystalequityresearch.com/leading-indi... - #smallcap

Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne MDxHealth (NASDAQ: MDXH) reported strong Q2 2025 results and announced a strategic acquisition. The company achieved $26.6 million in revenue, marking a 20% year-over-year increase and its 17th consecutive quarter of 20%+ growth. Notably, MDxHealth reached positive adjusted EBITDA of $1.4 million in Q2.The company announced the acquisition of Bio-Techne's ExoDx business for $15 million, to be paid in cash and stock over 5 years. The deal includes the ExoDx Prostate test and CLIA-certified laboratory. The acquisition is expected to contribute over $20 million in revenue by 2026 and accelerate revenue growth to approximately 30%.Q2 highlights include a 74% improvement in operating loss to $1.9 million, tissue-based test volume growth of 26%, and liquid-based test volume increase of 18%. The company reaffirmed its 2025 revenue guidance of $108-110 million.

#MDXH Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne

www.stocktitan.net/news/MDXH/mdxhealth-repo...

MDxHealth Earnings Reveal 16-Quarter Growth Streak as Diagnostics Giant Nears Profitability Milestone Q1 marks 16th straight quarter of 20%+ growth with 71% EBITDA improvement. See how MDxHealth's precision diagnostics expansion drives path to Q2 profitability. Get insights.

#MDXH MDxHealth Reports Q1-2025 Results

www.stocktitan.net/news/MDXH/m-dx-health-re...

Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results MDxHealth (NASDAQ: MDXH) reported strong Q4 and full-year 2024 financial results, with 28% revenue growth in both Q4 ($24.7 million) and full-year ($90.0 million). Q4 highlights include a 68% improvement in adjusted EBITDA to ($1.4) million and significant test volume increases: tissue-based tests up 50% and liquid-based tests up 10%.Q4 gross profit increased 22% to $15.5 million with margins at 62.7%, while operating expenses rose 6% to $20.1 million. Net loss decreased 36% to $6.8 million. For full-year 2024, gross profit grew 26% to $55.1 million with 61.2% margins, and net loss improved 12% to $38.1 million.The company maintains its 2025 revenue guidance of $108-110 million and expects to achieve adjusted EBITDA profitability in H1 2025. Year-end cash position stands at $46.8 million.

#MDXH Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results

www.stocktitan.net/news/MDXH/mdxhealth-anno...

NEWS: ( NASDAQ: #MDXH ) MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance

MDxHealth Reports Strong 28% Revenue Growth, Projects EBITDA Profitability in 2025 MDxHealth achieves $90M revenue in 2024 with 28% YoY growth. Company forecasts $108-110M revenue for 2025 and expects adjusted EBITDA profitability in first half.

#MDXH MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance

www.stocktitan.net/news/MDXH/m-dx-health-re...

#MDXH MDxHealth to Participate in Piper Sandler Healthcare Conference

www.stocktitan.net/news/MDXH/m-dx-health-to...

News; ( NASDAQ: #MDXH ) MDxHealth Reports Preliminary Q2 and Half Year 2024 Revenues and Raises 2024 Revenue Guidance

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #MDXH ) Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors

#StockMarket #News